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The gap between academic research and the commerzcialization of research result
can be overcome with the founding angels investment model where very early
stage investors found start-up companies together with appropriate research
partners to conduct research and later, alone or togetherwith industrial partners,
commercialize the results. The engagement of founding angels is compensated
not monetarily but through an equity share of the new company. This business
model is already being implemented in the United States with some interesting
examples in the area of nanotechnology. This article analyses approach and
investment strategy as well as defines a best practice process of founding angels
as early stage technology investmentmodel applying an exploratorymultiple case
analysis. The empirical data are based on literature research with a focus on
document analysis and interviews with 35 nanotechnology experts.
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advanced protective coatings. Chemical
companies such as BASF, Bayer, DSM, DuPont,
GE, Honeywell, Mitsubishi and Rohm and Haas
have also begun to invest heavily in
nanotechnology. These firms are developing, for
example, scratch resistant polymers, super
insulating wire coatings or batteries with longer
shelf life. HP, IBM, Lucent and Motorola have
turned to nanotechnology for the next
breakthroughs in semiconductor manufacturing.
These companies have also invested in
developing super capacity data drives and nano
emissive displays.
Governments worldwide are recognizing the
importance and potential of nanotechnology
(Roco, 2005) and the number of patents is
continuously growing, led by the United States
(US) and Europe (Chen et al., 2008).
But a gap can be identified between academic
research and the commercialization of research
results, which represents a serious barrier for
innovation. This gap can be overcome with the
founding angels investment model where very
early stage investors proactively found start-up
companies together with appropriate research
partners to conduct research and later, alone or
together with industrial partners, commercialize
Introduction
Nanotechnology is a broad term that refers
to anything engineered down to the nanometer
scale. It provides the ability to isolate and
manipulate single atoms, which behave much
differently than clustered atoms. This change
in behaviour is due to an increased relative
surface area, producing more chemical reactivity,
and the dominance of quantum effects, altering
the material's optical, magnetic and electrical
properties. The aim is to unlock capabilities in
materials by manipulating them at the atomic
level. Building at the nanometer scale allows
scientists and engineers to design specific
magnetic, thermal, and strength properties into
products. Nanotechnology is expected to play
a key role in the 21st century with large market
potentials in numerous applications.
Companies such as 3M have been leading
the change, citing nanotechnology as a primary
driver for future revenue and technology growth.
3M has been working on nanomaterials since
1985 when it started using nanostructures in
its film coatings. 3M is now expanding into
developing biomedical sensors, new metal
matrix composites, strong adhesives and
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formal investors, for example venture capital
companies (Fried and Hisrich, 1994; Kaplan and
Strömberg, 2001). Venture capital companies
normally invest only in companies that have at
least proceeded beyond the product
development stage (Branscomb and Auerswald,
2002) and they even prefer to invest when the
technological potential is demonstrated by
working together with first customers.Therefore,
the informal venture capital market is vital for
early stage high-tech companies (Wetzel and
Freear, 1996) and since the early nineties,
politicians and researchers have increased their
interest in understanding how the informal
venture capital market works and how it can be
optimised. For example, in the US and the United
Kingdom (UK), the largest source of risk
financing comes from business angels (Mason
and Harrison, 1996). Globally speaking, the
business angels’ investment in new technology-
based firms is twice as large as formal venture
capitalists’ investment (Bygrave and Quill, 2007).
Support by business angels
Due to their function of the “missing link”,
business angels help bridge the financial gap
in the high risk early stage phase (Mason, 2006;
Maunula, 2006). Having been financed by busi-
ness angels raises the credibility of the company
in the eyes of potential partners and thus
increases the chances of the company receiving
further investment. Ideally, business angels
complement venture capital companies,
especially with regard to the size of the
investment, the value added and the investment
phases (Crawley, 2007) and provide a deal flow
for venture capital funds (Madill et al., 2005).
BAs in the U.S. account for double the amount
of investments (in terms of deal size) in start-
ups when compared to VCs (Riding 2008; Bygrave
and Quill 2007). On the other hand, a recent
Canadian study has shown that the 3F funding
(from family, friends and fools) accounts for
more than three times as much annual
investment as BAs (Riding 2008).
Business angels choose to invest in specific
sectors based on their previous experience and
a strong network (Van Osnabrugge, 2000).
Mason and Harrison (2002) have noticed that
business angels are, in general, looking for more
investment opportunities. This is mainly due to
the fact that most of the proposals they receive
do not coincide with their investment criteria.
For example, in the industry or technology sector,
the company stage or location may not fulfil
their conditions. Also, many investors do not
the results.
This paper discusses early stage technology
investments in the area of nanotechnology by
founding angels. 
In the first part we analyse a typical
innovation process in nanotechnology and the
role of start-up companies taking carbon
nanotubes (CNTs) as an example. Then we show
case examples of professionals using the
founding angels investment model in the area
of nanotechnology. Based on the investigation
of the innovation process and the case examples
we then analyse the founding angels investment
model, define a best practice investment process
and discuss the investment strategy.
Literature review
Importance of start-up companies
In many cases of innovation processes a
technology transfer gap exists between
academic research and the commercialization
of the results to realise industrial applications.
This gap can be closed through start-ups as they
facilitate the transfer of research results into
products. Therefore, they are important for
innovation and an accelerator of economic
growth, especially in high-tech areas like
nanotechnology, targeting markets with high
growth potentials (Roberts, 1991; Heirman and
Clarysse, 2004; Stam et al., 2009). The
importance of start-ups is also seen by
universities (Shane, 2002). Generally, academic
researchers neither have the knowledge nor the
experience to commercialize their research
results (Litan and Mitchell, 2007). To facilitate
technology transfer from academic research to
industrial applications many universities have
implemented technology transfer offices (TTOs)
(Goldfarb and Henrekson, 2003). Most TTOs
recognise start-ups as an interesting method of
technology transfer and thus help scientists in
their entrepreneurial efforts (Feldman and Feller,
2002; Markman et al., 2005; Meyer, 2006).
Acquiring enough capital is a serious
challenge for many start-ups, especially in early
stages. Particularly for high-tech start-ups the
necessary resources are relatively high in the
first stages, due to the steep cost of research
and product development. There are three finan-
cial sources which founders can rely on. The first
is the government, which can inject money into
start-ups through governmental programmes.
The second financial source is private investors
like business angels, who are normally referred
to as informal investors. The third source is
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Founding angels as new investment model
An analysis of established business models
in the area of start-ups shows that known play-
ers, such as technology transfer offices at
universities and research institutes and business
plan competitions, are only active in parts of
the value chain (Figure 1). Business angels and
venture capital companies are normally focused
on already founded companies. Especially
venture capitalists do not play an important role
in early stage technology investments. This gap
in the pre-seed and seed phase before start-ups
are founded can be closed by the founding
angels business model (Festel and Boutellier,
2008).
Founding angels are engaged with the
scientists before the start-up is founded and
they are part of the founding team (Festel and
Boutellier, 2008; Festel et al., 2010). They play
an important operational role in the build-up
phase of the start-up based on their specific
industry or functional know-how e.g. in the field
of financing, intellectual property (IP)
management or licensing.
The founding angels investment model can
be realised by both private persons and profes-
sional teams. By way of comparison to business
angels, the private persons can be defined as
founding angels. Like business angels they are
generally not visible so it is very difficult to
identify them - especially as they themselves
are unaware of the fact that they are founding
angels, as the term "founding angels" in this
context is relatively new. For this reason, the
research in this paper is focused on professional
teams using the founding angels investment
model. These are organised similar to venture
capital teams with most of them coming from
the venture capital area. In the field of
nanotechnology there are some interesting
examples of these very early stage technology
investors, especially in the US. 
The founding angels investment strategy
offers clear advantages (Festel, 2011). Due to
their engagement at an early stage in the new
start-up company, there is little competition
with other investors and a large opportunity to
ensure attractive investment possibilities with
a high value creation potential. Due to this fact
and the relatively low initial investment volume
needed for the pre-seed stage, a large number
of investments or engagements can be achieved.
This diversification will allow founding angels
to expect higher returns due to a lower total
risk. 
possess the necessary technical knowledge
required for investing in high-tech areas. Finding
a good opportunity takes much effort due to a
lack of access to the academic researchers and
the long selection process (Mason and Harri-
son, 1992). 
Because of this time consuming procedure,
more and more investors have neglected small
investments in order to focus on bigger deals
(Murray, 1999). This theory is confirmed by Mason
and Harrison (1995) who attribute the equity
gap to the high search cost of business angels
seeking investment opportunities. According to
Zhang (2009), this can also be overcome with
the help of experienced people. They are faster
than novices in acquiring resources due to an
established network and working experience
with people like venture capitalists and
customers. They also know how to handle
information asymmetry during the financing
process, which is due to the fact that founders
rarely paint a precise picture of the company
(Binks et al., 1992). 
Especially during the creation of a start-up,
scientists as entrepreneurs face several chal-
lenges in order to develop the technology,
strengthen the company and generate revenue
as early as possible (Baron, 1998). The scientist
is often absorbed by his daily duties and chal-
lenges in research and has quite often a biased
view on how his research output could be used.
Besides capital, new technology based
companies very often lack business know-how,
as the founders are usually highly research
orientated scientists. This means, that besides
enough capital, a start-up also heavily relies on
operational assistance in order to be successful
and additional knowledge provided by informal
investors is often required and sometimes valued
as a financial investment, in return for shares
(Crawley 2007). Thus, the working relationship
between founders and business angels is
important and it should start as early possible
(Landström, 1998). The earlier in the development
process the relationship between founders and
investors are established, the less likely conflicts
regarding goals or tasks will occur, whereas these
conflicts have been demonstrated to lead to
investors’ or entrepreneurs’ exit (Collewaert
2011). Unfortunately, business angles normally
do not have enough time to build a solid rela-
tionship with the founders (Ensley et al., 2002).
Another important aspect is that because
business angels normally only invest in existing
companies, their work cannot help bridge the
gap between academic research and industrial
application if insufficient start-ups are founded. 
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document and literature analysis, interviews,
and observations. Our multiple case study
includes desk research with a focus on document
analysis and interviews with 35 nanotechnology
experts.
Empirical data
Between 2006 and 2008, 35 nanotechnology
experts from industry, government, academia
and the finance sector were interviewed to learn
more about the identification and analysis of
the mechanisms to successfully commercialize
nanotechnology as well as the hurdles and the
solutions to overcome these hurdles. A reference
set of questions was developed as a guideline
for the interview, leaving enough room for
spontaneous answers, which gave a semi-
structured nature to the interviews. Before each
interview, the authors had gathered in-depth
information on the company or institution
through various public sources (e.g. databases,
website, press releases), enabling an efficient
conduct of the interviews. 
Literature analysis was conducted in 2008
Methodology
Research approach
The research is explorative in nature and
therefore applies a case study research. The
single case study focuses on unique,
representative, extreme or not accessible cases
which have been analysed over a longer period
of time. It aims at falsifying theoretical insights
or to provide new insights in unexplored
phenomena (Yin, 2003; Yin, 2006; Borchardt and
Göthlich, 2007). The multiple case study method
compares cases and highlights resulting insights
through similarities and dissimilarities between
the cases (Borchardt and Göthlich, 2007). We
selected to apply a multiple case study approach,
as numerous authors consider results from
multiple case studies as more convincing,
trustworthy, and robust (Eisenhardt, 1989; Yin,
2003). Within this research design different
sources of data, qualitative and quantitative
data, can be included (Flick, 1995; Yin, 2006). The
data collection methods for case studies are
Business
idea
Business
concept
Business
plan
Start-up
founding
Start-up
financing
Offices
and labs
Business
development
Technology
transfer
Business plan
competitions
Consultants
Venture
capital
Business
angels
Technology
centres
Start-up founding and
financing process
Screening Pre-Seed Seed
Start-
up Growth
Founding
Angels
Business Angels
Venture Capital
Figure 1 Business models in the area of start-ups (Festel and Boutellier, 2008)
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objectivity, and by recording the interviews with
an audio device, ensuring evaluation objectivity
(Yin, 2003).
Results and discussion
Innovation process and start-ups
Nanotechnology know-how is mainly used
in the early stages of the value chain, i.e. the
stage of components and intermediate products
or production and analysis technologies. The
value added is normally reached through
performance enhancement in the whole system
or the end product, the commercialization of
which is carried out by end product producers
in different industrial sectors. A good example
is CNTs, which was especially investigated
through the expert interviews. This innovative
nanomaterial enhances the mechanical proper-
ties of plastics and other materials. In sporting
goods, for example, Wilson uses nanotech to
produce tennis balls that do not deflate as
quickly as traditional ones. Another application
example is in the production of tennis racquets
with improved properties. Due to the high price
of CNTs and their high production costs, these
racquets are significantly more expensive than
traditional ones. 
From an end product producer's viewpoint,
these materials can only establish in the market
on a broader basis through lower prices. In order
to realise lower prices, producers of CNTs, who
are at the beginning of the value chain, need to
invest in new production processes and facilities.
This problem could be solved through co-
operations between the material producers,
polymer compounders, system suppliers and
end product producers combining "technology
push" and "market pull" effects. Practice shows,
however, that with cooperations between
established companies such developments take
a long time. This lies mainly in the fact that such
projects are neglected for daily business and, of
course, the well-known problems of innovation
processes in large organisations.
Start-ups can play an important role in the
rapid transfer of research results into products
as they are highly motivated, very focused and
flexible. For example, start-ups in the area of
CNTs, like Future Carbon, speed up the innovation
processes along the value chain. They develop
and provide the technology to produce special
CNT formulations which are necessary for
product development on the following value
chain step (Figure 2). Polymer processing
companies, like Freudenberg, have only low
in order to be able to describe and understand
the founding angels business model. This was
the first time that the expression founding an-
gels was used in the scientific literature to
describe very early stage investors engaged in
prefounding projects (Festel and Boutellier,
2008). A second phase of literature research took
place from 2010 to 2011, during which the results
of the first literature research were updated
and, furthermore, additional founding angels
identified in order to better analyse the business
model. Based on the interviews and literature
analysis, 12 founding angels case studies were
created from which the five most interesting
and fitting case studies are presented in this
paper.
Analysis and research quality assurance
Particularly when conducting explorative
research, applying a multiple case study
approach and analysing qualitative data research
quality assurance based on the criteria reliability,
validity, and objectivity becomes very important
(Albers et al., 2007; Lamnek, 2008; Bortz and
Döring, 2005; Yin, 2003). As Yin (2006) stated,
reliability of qualitative research can only be
achieved by a structured way of proceeding and
by exactly documenting the research process
and its results. Therefore, all facets and steps of
our qualitative research were discussed with
other researchers and performed in a structured
way. The analyses of the data were conducted
systematically and in multiple iterations. First,
all information gathered through our literature
research was categorised, explored and analysed.
Second, based on step one, a semi-structured
interview guideline was developed and tested.
Third, 35 interviews were conducted. Fourth, the
interviews were transcribed and condensed over
several iteration steps up to a point at which
only the key insights of each case was remaining.
During the analysis, each case was analysed by
describing it and performing a short within-
case analysis. Afterwards, all cases were
compared to each other by executing a cross
case analysis. And finally fifth, the resulting
output from the interviews and literature
research were combined and discussed with
other researchers and practitioners.
Validity of the research was achieved by data
and method triangulation, documentation of
chains of evidence, or the discussion of
preliminary case study results with the research
participants (Yin, 2003). Objectivity was ensured
by having the same person conducting the semi-
structured interviews, guaranteeing execution
Gunter Festel and Jan Kratzer
Journal of Business Chemistry 2012, 9 (1)© 2012 Institute of Business Administration 24
experience and resources to develop these for-
mulations in-house. CNT producers, like Bayer
on the other hand, are too large to focus on this
kg business as their strategy is to produce
thousands of tonnes.
Founding angels case studies
The aim of presenting the case studies is to
show their approach to foster the creation of
start-up companies. 
Some of the case studies are only active in
the area of nanotechnology, like Advance
Nanotech, Arrowhead Research Corporation or
Molecular Manufacturing Enterprises, while
others have a broader technological scope, like
Angle Technology or Arch Venture Partners
(Table 1). Most of the activities are located in the
US and one in the UK. 
Advance Nanotech
Remark: The provided information is from
2008, as no current information could be found
(e.g. the company website is no longer available).
Founded in 2003, Advance Nanotech focused
on nanotechnology for applications in elec-
tronics, biopharma and materials. They identified
patented, patent-pending and proprietary
technologies at leading universities and funded
the additional development of such technolo-
gies in exchange for the exclusive rights to
commerzialise any resulting products. In-house
competence was used to accelerate the
development of multiple early stage research
programmes to proof-of-concept or demonstrate
manufacturability within three years.
Advance Nanotech maintained a controlling
interest in a broad portfolio of nanotechnology
projects, each with a defined capital
commitment. In order to ensure a high success
rate for the portfolio, each project went through
an assessment process to ensure that each
technology was still en route to successful
commercialization. As the project progressed,
preset milestones had to be accomplished for
continued investment. These milestones were
reviewed on a regular basis for continued
funding, redirection of funds or withdrawal of
investment. The projects were generated within
partnerships with academic institutions like the
Universities of Cambridge and Bristol as well as
Imperial College London. By partnering with
universities and leveraging the infrastructure
and human resources of the university partners,
individual project costs were low.
After prototypes were proven within the lab
and a product roadmap and business plan had
been developed, majority owned subsidiaries
around the specific technology were formed.
Additional money was sought through the sale
or licensing of the technology, by securing
additional financing from either the venture
capital community, or by successfully executing
the business plan and consolidating its income
as the majority shareholder. Once a product was
ready for market, in some cases, further funding
was accessed from the capital markets by listing
companies on the stock market. 
Portfolio companies of Advance Nanotech
were Advance Display Technologies, Advance
Homeland Security, Bio-Nano Sensium, Nanofed,
Nano Solutions and Owlstone Nanotech. From
2007, Advance Nanotech was publicly traded in
the US on the over-the counter (OTC) market.
Starting as "over-the counter bulletin board"
share with the requirement to file current
financial statements with the US Securities and
Exchange Commission (SEC) or a banking or
insurance regulator they became "pink sheet"
shares (symbol AVNA.PK) with no need to meet
minimum requirements or file with the SEC.
Figure 2 Carbon nanotube value chain
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omerics, NeuroTargets, Novocellus, Parsortixand
Synature. For example, Novocellus is a diagnostic
company founded to commercialize technology
from the University of York for non-invasive
testing of the viability of in vitro fertilisation
embryos. Additionally, Angle has performed two
exits with Exago and Provexis. The projects are
sourced from world class research
establishments, such as UK Defence Science &
Technology Laboratory, the universities of Bristol,
Cambridge and York and the Rowett Institute,
and in the US, from the universitites of Southern
California and New York. 
Angle seeks to retain a substantial
shareholding in these companies with a view
to ongoing returns from dividend, milestone,
royalty and capital returns. The average age of
the portfolio companies is six years and they
have been developed to the stage where the
portfolio, as a whole, is substantially cash-
independent of Angle, thereby presenting Angle
shareholders with the potential for substantial
upside returns without a corresponding
downside risk of further investment. Over the
last two years, Angle has deployed a deliberate
strategy to focus its efforts and resources on
the winners within the portfolio recognising
that, with early stage technology investment,
successful returns are likely to be concentrated
in a relatively small number of investments,
which may be big winners.
Angle is quoted on the London Stock
Exchange at the AIM market (symbol AGL.L). AIM
Currently (end of May 2011), the share price is
nearly zero. 
Angle Technology
Angle was founded in 1994 and is
headquartered in the UK with a technology
commercialization subsidiary in the US. The
company focuses on the commercialization of
technologies and the development of
technology-based start-ups. Besides its
consulting business on a fee-for-service basis
and the operation of science & technology parks,
Angle has founded and developed a portfolio of
start-ups in which it retains substantial equity
stakes. Technologies sought are those at pre-
seed/seed stages and were selected for their
strong IP platform. The IP should have been
granted or close to being granted and it has
been demonstrated that the technology works.
The Angle team consists of professionals with
backgrounds that combine business, finance
and entrepreneurial expertise, with scientific
and technical knowledge. The management
support for the start-ups includes the building
of the senior management team, conducting
market research, developing the business plan,
and overseeing product development, as well
as market entry strategies.
The portfolio spans from medical and life
sciences, cleantech and physical sciences to IT
and software. The current portfolio consists of
the six companies Acolyte Biomedica, Ge-
Table 1 Case studies of the founding angels investment model
Name Intenet Locations Technology areas Financialsources
Advance Nanotech www.advancenanotech.com(not available) Montebello (US) Nanotech
Public (US OTC
market: AVNA.PK)
Angle Technology www.angletechnology.com Guildford (UK)
Cleantech,
lifesciences, physical
sciences, ICT
Public (London
stock exchange
AIM: AGL.L)
Arch Venture
Partners www.archventure.com
Chicago, Seattle,
Austin, San
Francisco (all US)
ICT, lifesciences,
physical sciences,
nanotech, biotech
Private
Arrowhead Research
Corporation www.arrowres.com Pasadena (US)
Nanotech/
nanomedicine
Public (NASDAQ
Capital Market:
ARWR)
Molecular
Manufacturing
Enterprises
www.mmei.com Saint Paul (US) Nanotech Private
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financial, administrative, corporate and strategic
resources. As a public company, there is access
to the public markets for the purpose of raising
capital and provide meaningful incentives in
the form of stock options to attract the most
talented managers and scientists. By offering
financial, administrative, corporate and strategic
resources to their subsidiary companies, each
individual management team can maintain
focus on specific technologies and specific
markets, increasing the likelihood of successful
technological development and commer-
zialisation. 
Currently, Arrowhead has the four majority-
owned subsidiaries Ablaris, Calando, Leonardo
Biosystems and Nanotope commerzialising
nanotech products and applications, including
anticancer drugs, RNAi therapeutics, fullerene
antioxidants, carbon-based electronics and
compound semiconductor materials. Since 2004,
Arrowhead is quoted on the NASDAQ Capital
Market (symbol ARWR). The NASDAQ Capital
Market, previously called NASDAQ Small Cap
Market, was renamed in 2005. Starting with 7
USD in January 2004, the highest stock price
was 7.50 USD in June 2004 and 7.60 USD in April
2007. The current price (end of May 2011) with
0.56 USD is near the all time low of 0.39 USD in
January 2009.
Molecular Manufacturing Enterprises
Molecular Manufacturing Enterprises
Incorporated (MMEI) is a seed capital firm
helping individuals or small groups to develop
a laboratory-bench model into a working
prototype that might then, in turn, interest a
venture capital firm. MMEI has a good working
relationship with the Foresight Institute (FI) and
with the Institute for Molecular Manufacturing
(IMM). FI is dedicated to educating the public
and policy makers about the advantages and
consequences of molecular nanotechnology.
IMM focuses on providing research funding,
with an emphasis on pure research. 
MMEI has the resources to provide modest
amounts of financial assistance to several high-
risk/highleverage efforts to advance the state
of the art of molecular nanotechnology. In addi-
tion, MMEI can provide technical and non-
technical advice and can also serve as a contact
point for people working towards advancing the
field of molecular nanotechnology. MMEI was
founded by three people with strong scientific
and financial backgrounds. In addition, MMEI
uses several advisors from a variety of areas,
both technical and nontechnical. The advisors
is the London Stock Exchange’s international
market for smaller growing companies. A wide
range of businesses including early stage,
venture capital backed as well as more
established companies join AIM seeking access
to growth capital. Starting in June 2006, with
a share price of 86 GBP and the minimum in
December 2008 with 7.5 GBP, the share price is
currently (end of May 2011) at 25 GBP.
Arch Venture Partners
Arch Venture Partners was spun off from an
initiative by the University of Chicago in 1986
as a not-for-profit affiliate corporation. Although
the company separated from the university in
1992, the university still remained a special
limited partner and investor. Arch Venture
Partners is one of the largest providers of seed
capital in the US with over USD 1.5 billion under
management. Its first fund was launched in 1989
and the sixth in 2003. A partnership led by
partners joined by a team of investment
managers and advisors. It has offices in San
Francisco, Seattle, Austin, Chicago, and Boston.
Arch Venture Partners has cofounded with
scientists and entrepreneurs or led the seed
round for more than 130 start-ups using scientific
discoveries from over 40 major research
universities. Arch Venture Partners focuses on
IT, life sciences, and physical sciences, with 95%
of its investments at the seed and start-up stage.
Special competence is in the building of start-
ups from research originating in academic and
research laboratory settings. Their business
model is to invest conservatively in a seed round
and then to lead and colead additional rounds
to liquidity. They also play an active role in
assisting portfolio company management.
Arrowhead Research Corporation
Arrowhead Research Corporation sponsors
research at university level in exchange for rights
to commercialize the IP that results. The
company works closely with universities to
source early stage deals. By funding the launch
of companies, rather than investing in them at
a later stage, Arrowhead obtains rights to the
IP without having to pay for all of the overhead
costs associated with R&D. When the
technologies are ready to leave the lab, start-
ups are formed and additional financing and
support services are provided and, if necessary,
a broader investor syndicate for a follow-on
round is organised. Arrowhead maintains a
majority interest in its subsidiaries and provides
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Intensive technical and nontechnical advice from
the founding angels is provided to the start-
ups. This includes conducting market research,
supporting product development and
establishing market entry strategies. A new
management team will take over responsibility
from the interim management organised by the
founding angels. Preset milestones are used to
assess the progress of the research projects with
regard to continued investment, redirection of
funds or withdrawal of investment. 
Phase 4: Development of the business
The focus is on building up a sustainable
business for the start-up by acquiring co-
operation partners and customers. Revenues are
generated through the sale or licensing of the
technology, by securing additional financing
from either the venture capital community or
the capital markets, or by successfully executing
the business plan and using own cash flow. If
necessary, a broader investor syndicate for a
follow-on financing is organized by the founding
angels. 
Phase 5: Execution of an exit
The exit will enable founders, founding angels
and other investors to get payed off. Universities
or research institutions will also profit if they
have an equity stake in the company. In most
cases a trade sale to existing industrial co-
operation partners of the start-up company is
realised.
Comparison with established models
Comparing founding angels, business angels
und venture capitalists shows that these in-
vestment models fit perfectly together. Founding
angels are engaged in very early stage projects
(pre-seed and seed stage), business angels in
early stage projects (mostly seed and start-up
stage) and venture capitalists more in later stage
projects (mostly growth stage and only a few
specialised companies in the start-up stage).
There are also case examples, like Arch Venture
Partners, combining the established venture
capital and the emerging founding angels
investment model as they primarily invest in
companies co-founded with scientists and entre-
preneurs. Because founding angels fund pre-
seed ventures, their average exit horizon is much
longer than their average venture capital fund
manager counterpart’s. Due to this long exit
horizon, both the entrepreneur and the founding
include a broad range of business, legal, and
financial experts.
Model of founding angels
The model of founding angels is the
combination of management and capital. They
build a bridge between the early stage research
and development (R&D) phase and a marketable
product by funding additional development at
universities and providing access to further
funding once a product is ready for the market.
After analysing the case studies, it has been
found that the following process with five
different phases provides a best practice
framework for founding angels investments. 
Phase 1:  Screening/sourcing of projects
Project opportunities are sourced and
evaluated to identify those which have the
highest potential and the best fit. If necessary,
founding angels finance early stage research at
universities or research institutions in exchange
for IP rights. The founding angels work together
with industry and technology experts to identify
and pursue these new opportunities in targeted
industries. These experts work closely together
with the scientists from the universities or
research institutions to develop a business plan.
Phase 2: Foundation of start-ups
When the technology is ready (e.g. proof-of-
concept in the laboratory) a start-up company
is established together with the scientists after
developing a business plan. The founding an-
gels provide seed capital for the development
of the start-ups as well as financial, administra-
tive, and strategic support. An agreement with
the universities or research institutions is signed
based normally on the exclusive rights regarding
all relevant IP. In exchange, the technology
partner receives a preagreed payment and/or
equity stake of the start-up. 
Phase 3: Building-up of the start-ups
The new company utilises the founding
angel's seed funding and management support
to build and operate the company, typically
focusing on R&D activities. The research focus
is on applied research up to the development
of a working prototype. The founding angels
also help start-ups to obtain access to additional
academic research laboratories and
manufacturing facilities should this be required.
angel have enough time to increase the value
of the start-up, which results in higher valuations
when additional funding is sought from large
venture capital funds. Increased value also
translates into a smaller dilution of stock
ownership in future rounds, an important
consideration for entrepreneurs and founding
angels. 
Advance Nanotech, Angle Technology and
Arrowhead Research are listed on public stock
markets. All of them had lost value continuously
during the last years. The negative development
of the stock price may lead to the conclusion
that the business model is flawed. We argue
that the business model in general is not flawed,
but that the concept of founding angel
investment is in strong contrast to the concept
of investing in public stock markets. Public
investors focus often on fast returns, but
technology start-ups need patient money with
an investment horizon of at least five to seven
years. Investors in public stock markets need
transparency and the information asymmetry
between investors and management is generally
overcome through financial statements, income
and cash flow statements, and balance sheets.
But technology start-ups generally have no
positive cash flows to analyse and the balance
sheet consists mainly of intangible assets, such
as patents and knowledge, which are hard to
value due to technological novelty and
complexity. 
Conclusion
After analysing founding angels as early stage
technology investors, they can be defined as a
relatively new investment model with the
potential to increase start-up activities, especially
at universities and research institutions. They
are active in high-tech sectors and invest at an
earlier stage of the start-up development than
other investors. Founding angels provide busi-
ness expertise and operational advice to identify
the mechanisms and actions needed to found
a new firm. With their innovative model,
founding angels are valuable for founders
because they i) invest time to support the
founders in the daily business, ii) have a vast
amount of knowledge, skills and experience, iii)
provide access to their networks.
Because of their profound market know-how,
founding angels help to broaden the view on
potential applications and they also keep an eye
out for new scientific breakthroughs which have
the potential of being commercialized.
Unrecognised commerzial potential can be
identified, and otherwise undiscovered
technologies or ideas make it to the market.
Thus, founding angels engagements have a “pull”
function in the venture business and they
significantly help to close the technology
transfer gap between academic research and
commerzial application. Because they work very
closely with the founders, the founding angels
will acquire a deep knowledge of the financial
situation or the technological potential of the
company. When facing important decisions such
as whether a large investment should be made,
a founding angel will decide differently than a
business angel or a venture capitalist, due to
his deeper and more complete information of
the company, which gives him an advantage.
An important limitation of our study relates
to the data gathering methodology. focus on
nanotechnology, which is (probably) a distorted
sample of the real population, might have
influenced our findings. In order to fully
understand the dynamics of FA activities, it
might be necessary to investigate engagements
with a broader technological scope. Given the
exploratory nature of this study, this problem
should be overcome in follow-up studies on the
subject.
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